ABVX:EPA
Abivax SA
€77.15
arrow_downward
-0.64%(-0.50) 1D
Nov 6, 5:36:06 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€74.45
High
€77.15
Low
€73.80
Mkt. cap
6.84B
Avg. vol.
111.44K
Volume
161.37K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
Open
€74.45
High
€77.15
Low
€73.80
Mkt. cap
6.84B
Avg. vol.
111.44K
Volume
161.37K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
The Motley Fool
·
1 hour ago
The S&P 500 Just Fell More Than 4% in a Day From Near Its Record. Here's What Happened Next in 2 Similar Situations Since 1950.
Reuters Connect
·
6 hours ago
A screen displays the Dow Jones Industrial Average after the closing bell on the floor of the NYSE in New York
qz.com
·
12 hours ago
Stock futures explained: how Dow, S&P 500 and Nasdaq-100 contracts work
StoneX
·
1 day ago
S&P 500 Forecast: SPX rebounds after strong NFP led by tech
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteabivax.com